About this trial
The aim of this clinical trial is to determine whether nicorandil works in minimizing disease severity in patients with rheumatoid arthritis. The study will also assess the safety and tolerability of nicorandil. The main questions it aims to answer are:
* Could nicorandil improve disease severity and symptoms of rheumatoid arthritis? * Does nicorandil lower the number of times participants need to use pain relieve medications? * Does the nicorandil improve participants functionality and ability to carry out daily activity? * Does nicorandil correct disease-associated damage and inflammation? * What side effects do participants have when taking nicorandil? Researchers will compare nicorandil to a placebo (a look-alike substance that contains no drug) to see if nicorandil works to decrease symptoms and severity of rheumatoid arthritis.
Participants will:
* Take nicorandil or a placebo two times daily for 3 months * Visit the clinic once every month for checkups * Keep a diary of their symptoms and the number of times they use a pain reliever
Eligibility criteria
Qualifiers
Adult (≥18 years).
Confirmed diagnosis with RA according to ACR/EULAR 2010 criteria.
Moderate to severe disease activity (DAS-28 ˃ 3.2).
Stable on conventional treatment for at least 3 months.
Disqualifiers
Other autoimmune diseases
Poor patient compliance
Malignancy or history of malignancy
Pregnancy or lactation.
Trial design
Treatments tested in this trial
- Nicorandil Oral Tablet
- Placebo
- conventional synthetic antirheumatic drugs (cDMARDs)